JP2017518748A5 - - Google Patents

Download PDF

Info

Publication number
JP2017518748A5
JP2017518748A5 JP2016568907A JP2016568907A JP2017518748A5 JP 2017518748 A5 JP2017518748 A5 JP 2017518748A5 JP 2016568907 A JP2016568907 A JP 2016568907A JP 2016568907 A JP2016568907 A JP 2016568907A JP 2017518748 A5 JP2017518748 A5 JP 2017518748A5
Authority
JP
Japan
Prior art keywords
polypeptide
glu
gly
arg
lipocalin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016568907A
Other languages
English (en)
Japanese (ja)
Other versions
JP6753784B2 (ja
JP2017518748A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/061034 external-priority patent/WO2015177175A2/en
Publication of JP2017518748A publication Critical patent/JP2017518748A/ja
Publication of JP2017518748A5 publication Critical patent/JP2017518748A5/ja
Application granted granted Critical
Publication of JP6753784B2 publication Critical patent/JP6753784B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016568907A 2014-05-22 2015-05-20 特異的結合ポリペプチドおよびその使用 Expired - Fee Related JP6753784B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14169488.5 2014-05-22
EP14169488 2014-05-22
PCT/EP2015/061034 WO2015177175A2 (en) 2014-05-22 2015-05-20 Novel specific-binding polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020139064A Division JP7084965B2 (ja) 2014-05-22 2020-08-20 特異的結合ポリペプチドおよびその使用

Publications (3)

Publication Number Publication Date
JP2017518748A JP2017518748A (ja) 2017-07-13
JP2017518748A5 true JP2017518748A5 (2) 2018-06-28
JP6753784B2 JP6753784B2 (ja) 2020-09-09

Family

ID=50771150

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016568907A Expired - Fee Related JP6753784B2 (ja) 2014-05-22 2015-05-20 特異的結合ポリペプチドおよびその使用
JP2020139064A Expired - Fee Related JP7084965B2 (ja) 2014-05-22 2020-08-20 特異的結合ポリペプチドおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020139064A Expired - Fee Related JP7084965B2 (ja) 2014-05-22 2020-08-20 特異的結合ポリペプチドおよびその使用

Country Status (14)

Country Link
US (2) US10774119B2 (2)
EP (2) EP3145945B1 (2)
JP (2) JP6753784B2 (2)
KR (1) KR20170004011A (2)
CN (2) CN113621050A (2)
AU (2) AU2015261968B2 (2)
BR (1) BR112016027024A2 (2)
CA (2) CA2949405C (2)
DK (1) DK3145945T3 (2)
ES (1) ES2823563T3 (2)
MX (2) MX384363B (2)
RU (1) RU2723034C2 (2)
SG (2) SG11201609274SA (2)
WO (1) WO2015177175A2 (2)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526384B2 (en) 2012-11-19 2020-01-07 Pieris Pharmaceuticals Gmbh Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
WO2015177175A2 (en) 2014-05-22 2015-11-26 Pieris Ag Novel specific-binding polypeptides and uses thereof
CN108699162A (zh) * 2015-11-30 2018-10-23 皮里斯澳大利亚有限公司 新型抗血管生成融合多肽
CN110506055A (zh) 2017-02-17 2019-11-26 戴纳立制药公司 工程改造的转铁蛋白受体结合多肽
CN111164104A (zh) 2017-08-09 2020-05-15 麻省理工学院 白蛋白结合肽缀合物及其方法
EP3665194A4 (en) * 2017-08-10 2021-07-07 Denali Therapeutics Inc. AFFINITY BASED METHODS OF USING TRANSFERRIN RECEPTOR BINDING PROTEINS
MX2020009265A (es) 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
AU2019275733B2 (en) * 2018-05-31 2025-07-31 The Chinese University Of Hong Kong Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities
EP3599245A1 (en) * 2018-07-27 2020-01-29 Dompé farmaceutici S.p.A. Il-17a binding polypeptides and medical uses thereof
CN109096373B (zh) * 2018-09-27 2022-06-21 江苏亨瑞生物医药科技有限公司 合成寡肽及其用途
CN109180789B (zh) * 2018-09-27 2022-08-19 上海揽微赛尔生物科技有限公司 一种寡肽及制药应用
CN109096374B (zh) * 2018-09-27 2022-11-18 深圳乐土沃森精准医疗有限公司 一种抑制肺癌转移的合成寡肽
CN109206485B (zh) * 2018-09-27 2022-04-08 山东聚胜生物科技有限公司 一种防治肺癌转移的寡肽
EP3946417A1 (en) * 2019-03-29 2022-02-09 Pieris Pharmaceuticals GmbH Inhaled administration of lipocalin muteins
US20210347880A1 (en) * 2020-05-05 2021-11-11 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
CN114805546B (zh) * 2022-06-08 2024-05-28 宁波市健康口腔医学研究院 一种检测口腔癌的t细胞表位多肽及其应用
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2025226984A1 (en) * 2024-04-24 2025-10-30 Mopac Biologics, Inc. Human il-17 binding polypeptides

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE76311T1 (de) 1986-08-19 1992-06-15 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
MX9605717A (es) 1994-05-18 1998-05-31 Inhale Therapeutic Syst Metodos y composiciones para la formulacion de polvo seco de interferones.
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
DK1087778T3 (da) 1998-06-08 2005-12-19 Hoffmann La Roche Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2003029471A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
AU2003264100A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of a bilin-binding protein with affinity for a given target
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
JP2009509535A (ja) 2005-09-27 2009-03-12 アムニクス, インコーポレイテッド タンパク様薬剤およびその使用
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
EP2046820B1 (en) 2006-08-01 2010-10-20 Pieris AG Muteins of tear lipocalin and methods for obtaining the same
ES2354653T3 (es) * 2006-08-01 2011-03-16 Pieris Ag Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas.
ES2708988T3 (es) 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009052400A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
CN101932598B (zh) * 2008-01-30 2016-12-21 皮里斯股份公司 具有对人c-met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法
DK3381933T3 (da) 2008-06-24 2020-08-03 Technische Universität München Muteiner af hngal og relaterede proteiner med affinitet til et givet mål
EP2330897A4 (en) * 2008-09-18 2013-11-27 Univ Columbia NGAL-BINDING SIDEROPHORES AND THEIR USE FOR THE TREATMENT OF IRON DEFICIENCY AND IRON SURPLUS
RU2707126C2 (ru) 2009-12-07 2019-11-22 Пирис Аг МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2, hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ
PL2580236T3 (pl) 2010-06-08 2019-09-30 Pieris Pharmaceuticals Gmbh Muteiny lipokaliny łez wiążące IL-4 R alfa
CN103003296A (zh) 2010-07-09 2013-03-27 阿菲博迪公司 多肽
EP3299386A1 (en) 2010-08-16 2018-03-28 Pieris Pharmaceuticals GmbH Binding proteins for hepcidin
AU2011331232B2 (en) * 2010-11-15 2015-05-07 Pieris Ag Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
GB201100282D0 (en) * 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP3842058B1 (en) 2011-12-13 2023-08-23 Pieris Pharmaceuticals GmbH Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
US10526384B2 (en) 2012-11-19 2020-01-07 Pieris Pharmaceuticals Gmbh Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
WO2015177175A2 (en) 2014-05-22 2015-11-26 Pieris Ag Novel specific-binding polypeptides and uses thereof
JP6839087B2 (ja) 2015-01-28 2021-03-03 ピエリス ファーマシューティカルズ ゲーエムベーハー 血管新生に特異的な新規のタンパク質
CR20170425A (es) 2015-02-18 2017-11-22 Sanofi Sa Nuevas proteínas específicas para pioverdina y pioquelina
CN114573680A (zh) 2015-05-04 2022-06-03 皮里斯制药有限公司 Cd137特异性的蛋白
MX2017014730A (es) 2015-05-18 2018-06-28 Pieris Pharmaceuticals Gmbh Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白

Similar Documents

Publication Publication Date Title
JP2017518748A5 (2)
RU2016149596A (ru) Новые полипептиды со специфическим связыванием и пути их применения
JP2018532372A5 (2)
JP2014502149A5 (2)
JP6475630B2 (ja) ストレプトアビジン突然変異タンパク質およびそれらを使用する方法
Alfthan et al. Properties of a single-chain antibody containing different linker peptides
Dübel et al. Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv)
JP2019506140A5 (2)
JP3474574B2 (ja) 結合特異性を有する組換ジスルフィド安定化ポリペプチドフラグメント
JP2017527272A5 (2)
JP2018519802A5 (2)
US8426557B2 (en) IGF-1R binding polypeptides and their use
KR102151289B1 (ko) Abd 결합 폴리펩티드
JP2018515084A5 (2)
JP2022500076A5 (2)
JP2020505948A5 (2)
JP2003518075A5 (2)
JP2018519803A5 (2)
RU2019122482A (ru) Мутеины липокалина с аффинностью связывания в отношении lag-3
KR20180002855A (ko) 항암 융합 폴리펩타이드
RU2017128105A (ru) Новые белки, специфические в отношении ангиогенеза
CN105968204A (zh) 一种抗前列腺特异性膜抗原的单域重链抗体
CN105968201A (zh) 针对前列腺特异性膜抗原的单域重链抗体
AU2007242584A2 (en) Novel polypeptides and use thereof
AU2019380620B2 (en) Novel triple-helical polypeptides lacking binding affinity for the Fc domain of immunoglobulin and uses thereof